Volume 15, Number 1—January 2009
Sphingomonas mucosissima Bacteremia in Patient with Sickle Cell Disease
Highlight and copy the desired format.
|EID||Angelakis E, Roux V, Raoult D. Sphingomonas mucosissima Bacteremia in Patient with Sickle Cell Disease. Emerg Infect Dis. 2009;15(1):133-134. https://dx.doi.org/10.3201/eid1501.080465|
|AMA||Angelakis E, Roux V, Raoult D. Sphingomonas mucosissima Bacteremia in Patient with Sickle Cell Disease. Emerging Infectious Diseases. 2009;15(1):133-134. doi:10.3201/eid1501.080465.|
|APA||Angelakis, E., Roux, V., & Raoult, D. (2009). Sphingomonas mucosissima Bacteremia in Patient with Sickle Cell Disease. Emerging Infectious Diseases, 15(1), 133-134. https://dx.doi.org/10.3201/eid1501.080465.|
To the Editor: The genus Sphingomonas was proposed by Yabuuchi et al. in 1990 (1) and amended by Takeuchi et al. in 1993 (2). It now has been subdivided into 4 separate genera: Sphingomonas sensu stricto, Sphingobium, Novosphingobium, and Sphingopyxis. The bacteria of the genus Sphingomonas are yellow-pigmented, nonfermenting, gram-negative bacilli with a single polar flagellum; they are widely distributed in the natural environment, especially in water and soil (3). These bacteria are characterized by the presence of a unique sphingoglycolipid with the long-chain base—dihydrosphingosin, ubiquinone 10 (Q-10), and 2-hydroxymyristic acid (2-OH C14:0)—and the absence of 3-hydroxy fatty acids (4). S. mucosissima was isolated and identified in 2007 by Reddy and Garcia-Pichel from biologic soil crust samples collected from sandy arid soil in the US Colorado Plateau (5). Sphingomonas spp. are opportunistic pathogens and have recently been implicated in a variety of community-acquired and nosocomial infections, considered to originate from contaminated hospital equipment or manipulation of some medical devices (3). The survival of Sphingomonas spp. in indoor dust particles as aerosols and their resistance to many disinfecting and toxic chemicals may explain their ability to colonize medical devices such as mechanical ventilators, catheters, and bronchofiberoscopes (6). In the past few years, these organisms, in particular S. paucimobilis, have been implicated in a variety of community-acquired and nosocomial infections.
We report a case of S. mucosissima bacteremia in a patient with sickle cell disease. In February 2008, a 17-year-old woman with homozygous sickle cell anemia was hospitalized when her condition suddenly became worse. The patient had undergone a splenectomy in 1992 and a cholecystectomy in February 2007. Four days after admission, she had a fever of 38.7°C. Two aerobic blood specimens, drawn on the fifth day of her hospitalization, yielded gram-negative bacilli after a 24-hour incubation. The gram-negative bacilli were positive for catalase and oxidase but remained unidentified by API 20NE strip (bioMérieux, Marcy l’Etoile, France). MICs of antimicrobial drugs were determined for the gram-negative bacilli by using an Etest assay (AB BIODISK, Solna, Sweden) on Mueller-Hinton medium. MICs were 1 μg/mL for cefotaxime, 1 μg/mL for amoxicillin–clavulanic acid, 2–3 μg/mL for vancomycin, 0.064 μg/mL for imipenem, 4–5 μg/mL for ceftazidime, 1 μg/mL for amikacin, 3 μg/mL for ciprofloxacin, and 0.047 μg/mL for trimethoprim-sulfamethoxazole.
DNA was extracted from 1 colony by using a QIAamp Tissue kit (QIAGEN, Hilden, Germany) as described by the manufacturer. A 16S rDNA sequence was obtained (1,410 bp) by using the fD1 (5′-AGAGTTTGATCCTGGCTCAG-3′) and rP2 (5′-ACGGCTACCTTGTTACGACTT-3′) primer pair (7,8). Using BLAST version 2.2.9 software (www.ncbi.nlm.nig.gov/BLAST), we determined that this sequence showed 98% similarity with the 16S rDNA sequence of S. mucosissima (GenBank accession no. AM229669). A phylogenetic neighbor-joining tree resulting from comparison of sequences of the 16S rDNA genes of Sphingomonas spp. was made with the MEGA 3.1 software (www.megasoftware.net). This analysis confirmed that the isolate belonged to S. mucosissima.
Initial treatment of intravenous administration of ceftriaxone was begun. The fever resolved after 1 day and the patient’s condition improved. Treatment was stopped after 5 days, and the patient remained apyretic. Two S. mucosissima isolates were recovered from 2 different blood-culture samples drawn 24 hours apart, which suggests that S. mucosissima was not just a transient organism but indeed was responsible for the patient’s septicemia. Phenotypic identification of the gram-negative bacilli failed because the definite bacterial species S. mucosissima was not included in the API database (http://industry.biomerieux-usa.com/industry/food/api/apiweb.htm) used for the phenotypic identification. However, the isolates’ biochemical characteristics were consistent with those previously reported for S. mucosissima (5) (Table). Final identification was achieved by comparing the almost complete 16S rDNA sequence with homologous sequences deposited in GenBank.
We believe that the patient’s intravenous catheter was the source of the infection because she did not have wound infections and cultures of her urine were negative for infectious agents. Antimicrobial drug treatment, selected on the basis of an in vitro S. mucosissima susceptibility profile, facilitated the patient’s recovery. This case report illustrates that the pathogenic potential of S. mucosissima should be considered in diagnosis in such cases because the organism can cause bacteremia in patients, primarily in those with underlying debilitating conditions and those who have undergone medical interventions.
- Yabuuchi E, Yano I, Oyaizu H, Hashimoto Y, Ezaki T, Yamamoto H. Proposals of Sphingomonas paucimobilis gen. nov. and comb. nov., Sphingomonas parapaucimobilis sp. nov., Sphingomonas yanoikuyae sp. nov., Sphingomonas adhaesiva sp. nov., Sphingomonas capsulata comb. nov., and two genospecies of the genus Sphingomonas. Microbiol Immunol. 1990;34:99–119.
- 2. Takeuchi M, Kawai F, Shimada Y, Yokota A. Taxonomic study of polyethylene glycol–utilizing bacteria: emended description of the genus Sphingomonas and new descriptions of Sphingomonas macrogoltabidus sp. nov., Sphingomonas sanguis sp. nov. and Sphingomonas terrae sp. nov. Syst Appl Microbiol. 1993;16:227–38.
- Ammendolia MG, Bertuccini L, Minelli F, Meschini S, Baldassarri L. A Sphingomonas bacterium interacting with epithelial cells. Res Microbiol. 2004;155:636–46.
- Kawahara K, Matsuura M, Danbara H. Chemical structure and biological activity of lipooligosaccharide isolated from Sphingomonas paucimobilis, a gram-negative bacterium lacking usual lipopolysaccharide. Jpn J Med Sci Biol. 1990;43:250.
- Reddy GS, Garcia-Pichel F. Sphingomonas mucosissima sp. nov. and Sphingomonas desiccabilis sp. nov., from biological soil crusts in the Colorado Plateau, USA. Int J Syst Evol Microbiol. 2007;57:1028–34.
- Lemaitre D, Elaichouni A, Hundhausen M, Claeys G, Vanhaesebrouck P, Vaneechoutte M, Tracheal colonization with Sphingomonas paucimobilis in mechanically ventilated neonates due to contaminated ventilator temperature probes. J Hosp Infect. 1996;32:199–206.
- Woo PC, Ng KH, Lau SK, Yip KT, Fung AM, Leung KW, Usefulness of the MicroSeq 500 16S ribosomal DNA-based bacterial identification system for identification of clinically significant bacterial isolates with ambiguous biochemical profiles. J Clin Microbiol. 2003;41:1996–2001.
- Kumar PS, Griffen AL, Moeschberger ML, Leys EJ. Identification of candidate periodontal pathogens and beneficial species by quantitative 16S clonal analysis. J Clin Microbiol. 2005;43:3944–55.
- Table. Biochemical characteristics of the previously reported Sphingomonas mucosissima isolate (AM229669) and the isolate from this study
Please use the form below to submit correspondence to the authors or contact them at the following address:
Didier Raoult, Unité des Rickettsies, CNRS UMR 6020, IFR 48, Faculté de Médecine, Université de la Méditerranée, 27 Blvd Jean Moulin, 13385 Marseille CEDEX 05, France; email:
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: November 22, 2010
- Page last updated: November 22, 2010
- Page last reviewed: November 22, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)